Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 4 records per page: next > | last >>
pages: 1 2 3 4 presentations: 1 to 25 of 86
Precision Medicine Early Clinical Trials
Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Udai Banerji
Inst. of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations. EORTC phase II trial 90101 "CREATE"
Patrick Schoffski
University Hospitals Leuven - Department of General Medical Oncology, Leuven, Belgium
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Ravi Salgia
City of Hope, Duarte, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results
Alexander Drilon
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
David S Hong
MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Leena Gandhi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Computational Cancer Epigenomics
Genome-scale analysis of DNA methylation in cancer: Discoveries, challenges, and opportunities
Hui Shen
Van Andel Research Inst., Grand Rapids, MI, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Computational Cancer Epigenomics
Prioritizing non-coding variants in cancer genomes using epigenetic profiles
Peter J. Park
Harvard Medical School, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Computational Cancer Epigenomics
Modeling cancer gene regulation with public ChIP-seq profiles
X Shirley Liu
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Large Animal Models for Solid Tumor Oncology
Transitional, technical, and biological approaches and advances to address unmet clinical needs
Lawrence B. Schook
University of Illinois at Urbana-Champaign, Urbana, IL, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Large Animal Models for Solid Tumor Oncology
Unmet clinical needs in oncology: The value of large animal models
George J. Weiner
University of Iowa Holden Comp. Cancer Center, Iowa City, IA, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Large Animal Models for Solid Tumor Oncology
The new pig on the block: Genome editing in cancer models
Angelika Schnieke
Technical University of Munich, Freising, Germany
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Large Animal Models for Solid Tumor Oncology
Organoid models and systems biology: From mouse to human
Michael M. Shen
Columbia University College of Physicians & Surgeons, New York, NY, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
The Pediatric Cancer Genome
Acute lymphoblastic leukemia
Charles G. Mullighan
St. Jude Children's Research Hospital, Memphis, TN, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
The Pediatric Cancer Genome
Credentialing genomic medicine in pediatric oncology: Neuroblastoma as a model
Yael P. Mosse
Children's Hospital of Philadelphia, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
The Pediatric Cancer Genome
Pediatric and adult high grade gliomas: A tale of a histone tail
Nada Jabado
McGill University Department of Pediatrics, Montreal, QC, Canada
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome
Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations
Vasiliki Michalarea
Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome
Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies
Zev A. Wainberg
UCLA Medical Center-Santa Monica, Santa Monica, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome
Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)
Geoffrey Shapiro
Dana Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome
A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings
Todd M. Bauer
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome
GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers
Peter J O'Dwyer
Univ. of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome
Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870)
Roberto Pili
Indiana University, Indianapolis, IN, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome
Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: a phase I study in advanced solid tumor malignancies
Pamela N Munster
UCSF, San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome
A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients
Nilofer Azad
Johns Hopkins University, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
<< first | < prev page: of 4 records per page: next > | last >>
pages: 1 2 3 4 presentations: 1 to 25 of 86